Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.
Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis / Ayala, Fabrizio; Balato, Nicola; Gaudiello, Francesca; Ayala, Fabio. - In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. - ISSN 0190-9622. - 50:(2007), pp. 63-63. [10.1016/j.jaad.2003.10.603]
Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis
AYALA, FABRIZIO;BALATO, NICOLA;GAUDIELLO, FRANCESCA;AYALA, FABIO
2007
Abstract
Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.File | Dimensione | Formato | |
---|---|---|---|
evaluation of efficacy.pdf
non disponibili
Tipologia:
Abstract
Licenza:
Accesso privato/ristretto
Dimensione
114.28 kB
Formato
Adobe PDF
|
114.28 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.